Torrent Pharma Appoints Shanti Ekambaram as Independent Director

Torrent Pharmaceuticals announced the strategic appointment of Shanti Ekambaram as an Additional Independent Director to its Board, effective July 30, 2026. This three-year term is contingent upon shareholder approval, bringing a wealth of experience to the pharmaceutical giant.

This decision, made by the Board following a recommendation from the Nomination and Remuneration Committee, aligns with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed Ekambaram has no familial ties to any other director and is not barred from office by SEBI.

A Career Defined by Financial Leadership

Ekambaram brings an impressive 39 years of experience spanning financial services and corporate governance. Her extensive background includes a pivotal 35-year tenure at Kotak Mahindra Bank, where she was instrumental in its transformation.

During her time, she helped evolve the institution from a pre-IPO non-banking financial company into a prominent universal bank. From 2022 to 2025, she served as Deputy Managing Director and Whole-time Director, overseeing several critical areas:

• Digital Banking
• Treasury
• Human Resources
• Internal Audit
• Vigilance
• CSR/ESG
• Capital Market subsidiaries

Pioneering Market Innovations

Beyond her banking leadership, Ekambaram also served as CEO of Kotak Mahindra Capital Company from 1997 to 2003. Here, she notably spearheaded the Hughes Software IPO in 1999.

This particular IPO marked India’s first book-building transaction, requiring significant collaboration with SEBI and other market participants. Her strategic input was crucial in refining the nation’s initial public offering mechanisms.

Broad Governance and Industry Recognition

Currently, Ms. Ekambaram holds directorships on the boards of several other key entities, showcasing her broad influence across the corporate landscape:

• Kotak Mahindra Capital Company
• Kotak Securities
• Havells India Limited
• Indian Institute of Management, Bangalore

Her professional achievements have garnered significant recognition, including being ranked No. 1 on the Candere Hurun India Women Leaders List 2025 and named Business Woman of the Year 2025 by The CEO Magazine. She has consistently featured on prestigious lists like Fortune India’s ’50 Most Powerful Women in Business’.

This appointment, adhering to SEBI regulations, signifies Torrent Pharmaceuticals’ strategic move to strengthen its board with deep financial acumen and corporate governance expertise. Ekambaram’s proven track record suggests a future where her insights will likely contribute to the company’s strategic trajectory and market positioning, pending shareholder approval.